TY - JOUR
T1 - Curcumin and genistein
T2 - The combined effects on disease-associated CFTR mutants and their clinical implications
AU - Sohma, Yoshiro
AU - Yu, Ying Chun
AU - Hwang, Tzyh Chang
PY - 2013
Y1 - 2013
N2 - Genistein and curcumin are major components of Asian foods, soybean and curry turmeric respectively. These compounds have been intensively investigated for their chemical and biological features conferring their anti-cancer activity. Genistein and curcumin have also been investigated for their potentiation effects on disease-associated CFTR mutants such as ΔF508 and G551D. Recently, we investigated the combined effect of genistein and curcumin on G551D-CFTR, which exhibits gating defects without abnormalities in protein synthesis or trafficking using the patch-clamp technique. We found that genistein and curcumin showed additive effects on their potentiation of G551D-CFTR in high concentration range and also, more importantly, showed a significant synergistic effect in their minimum concentration ranges. These results are consistent with the idea that multiple mechanisms are involved in the action of these CFTR potentiators. In this review, we revisit the pharmacology of genistein and curcumin on CFTR and also propose new pharmaceutical implications of combined use of these compounds in the development of drugs for CF pharmacotherapy.
AB - Genistein and curcumin are major components of Asian foods, soybean and curry turmeric respectively. These compounds have been intensively investigated for their chemical and biological features conferring their anti-cancer activity. Genistein and curcumin have also been investigated for their potentiation effects on disease-associated CFTR mutants such as ΔF508 and G551D. Recently, we investigated the combined effect of genistein and curcumin on G551D-CFTR, which exhibits gating defects without abnormalities in protein synthesis or trafficking using the patch-clamp technique. We found that genistein and curcumin showed additive effects on their potentiation of G551D-CFTR in high concentration range and also, more importantly, showed a significant synergistic effect in their minimum concentration ranges. These results are consistent with the idea that multiple mechanisms are involved in the action of these CFTR potentiators. In this review, we revisit the pharmacology of genistein and curcumin on CFTR and also propose new pharmaceutical implications of combined use of these compounds in the development of drugs for CF pharmacotherapy.
KW - Additive effect
KW - G551D
KW - Synergistic effect
UR - http://www.scopus.com/inward/record.url?scp=84887394805&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84887394805&partnerID=8YFLogxK
U2 - 10.2174/13816128113199990320
DO - 10.2174/13816128113199990320
M3 - Review article
C2 - 23331029
AN - SCOPUS:84887394805
SN - 1381-6128
VL - 19
SP - 3521
EP - 3528
JO - Current Pharmaceutical Design
JF - Current Pharmaceutical Design
IS - 19
ER -